Faculty introduction, disclosures

Review of cervical dystonia  Epidemiology: statistics of cervical dystonia and spasticity  Health burden Clinical features, presentation, diagnosis, and the risk of misdiagnosis

Treatment of cervical dystonia Goals of therapy  Monitoring response  Review of and evidence behind treatment options First-line: botulinum toxins  Product comparison and contrast  Initial dosing strategy  Length of treatment interval  Injection technique  Neutralizing antibodies and adverse effect mitigation  Second-line: anticholinergics, benzodiazepines, GABA agonists, dopaminergics, and anti-dopaminergics  Investigational therapies Treatment challenges Approach to primary and secondary non-responsiveness  Special populations: anticoagulation, pregnancy  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall the health burden of cervical dystonia.
• Describe the diagnosis of cervical dystonia and challenges associated with it.
• Identify the present and emerging treatment options for the management of cervical dystonia.
• Formulate a treatment plan for a patient with cervical dystonia.

ACCME Activity #202522667

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Hwai Yin (Evelyn) Ooi, MD, Assistant Professor of Clinical Neurology, Weill Cornell Medicine, has received financial compensation from research grants from Biogen, Sun Pharma Advanced Research Company, Genentech, Neuroderm, Bluerock, Novo Nordisk, and Insightec.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merz Pharmaceuticals.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version